Global Tissue Regeneration Market

1 INTRODUCTION OF GLOBAL TISSUE REGENERATION MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL TISSUE REGENERATION MARKET OUTLOOK
4.1 Overview

4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities

4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL TISSUE REGENERATION MARKET, BY COMPONENT:
5.1 Cell therapy
5.2 Stem cell therapy
5.3 Stem cell sources
5.4 Existing and development-stage stem cell products
5.5 Tissue vascularization
5.6 Cell culturing
5.7 Small molecules and biologics
5.8 Others

6 GLOBAL TISSUE REGENERATION MARKET, BY RAW MATERIAL:
6.1 Synthetic
6.2 Genetically modified
6.3 Biological

7 GLOBAL TISSUE REGENERATION MARKET, BY APPLICATION:
7.1 Cardiovascular disorders
7.2 Oncology
7.3 Dermatology
7.4 Musculoskeletal
7.5 Wound healing
7.6 Neurology
7.7 Ophthalmology
7.8 Others

8 GLOBAL TISSUE REGENERATION MARKET, BY END USER:
8.1 Hospitals
8.2 Clinics
8.3 Ambulatory centers
8.4 Research laboratories
8.5 Others

9 GLOBAL TISSUE REGENERATION MARKET, BY GEOGRAPHY
9.1 Overview

9.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico

9.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe

9.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific

9.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina

9.6 Rest of the World Regional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL TISSUE REGENERATION MARKET COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES

11.1 Arteriocyte Medical Systems Inc.
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 Athersys Inc.
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 Cerapedics Inc.
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 Co. Don AG
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 Cook Medical Inc.
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 Cryolife Inc.
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 Cytori Therapeutics Inc.
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 Genzyme Corp.
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 Kinetic Concepts Inc.
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments

11.10 Mesoblast Ltd.
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments

11.11 Nuo Therapeutics Inc.
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Developments

11.12 Ocata Therapeutics Inc.
11.12.1 Overview
11.12.2 Financial Performance
11.12.3 Product Outlook
11.12.4 Key Developments

11.13 Organogenesis Inc.
11.13.1 Overview
11.13.2 Financial Performance
11.13.3 Product Outlook
11.13.4 Key Developments

11.14 Orthopeutics L.P.
11.14.1 Overview
11.14.2 Financial Performance
11.14.3 Product Outlook
11.14.4 Key Developments

11.15 U.S. Stem Cell Inc.
11.15.1 Overview
11.15.2 Financial Performance
11.15.3 Product Outlook
11.15.4 Key Developments

12 Appendix
12.1 Related Reports